Akebia Ther (AKBA)vsTakeda Pharmaceutical Co Ltd ADR (TAK)
AKBA
Akebia Ther
$0.94
-3.61%
HEALTHCARE · Cap: $273.62M
TAK
Takeda Pharmaceutical Co Ltd ADR
$15.60
+0.97%
HEALTHCARE · Cap: $49.67B
Smart Verdict
WallStSmart Research — data-driven comparison
Takeda Pharmaceutical Co Ltd ADR generates 1938645% more annual revenue ($4.51T vs $232.40M). TAK leads profitability with a 4.3% profit margin vs -8.8%. TAK earns a higher WallStSmart Score of 57/100 (C).
AKBA
Avoid21
out of 100
Grade: F
TAK
Buy57
out of 100
Grade: C
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Growing faster than its price suggests
Reasonable price relative to book value
Earnings expanding 330.2% YoY
Areas to Watch
Trading at 9.4x book value
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
3.9% revenue growth
ROE of 2.5% — below average capital efficiency
4.3% margin — thin
Operating margin of 3.1%
Comparative Analysis Report
WallStSmart ResearchBull Case : AKBA
AKBA has a balanced fundamental profile.
Bull Case : TAK
The strongest argument for TAK centers on PEG Ratio, Price/Book, EPS Growth. PEG of 0.40 suggests the stock is reasonably priced for its growth.
Bear Case : AKBA
The primary concerns for AKBA are Price/Book, EPS Growth, Market Cap.
Bear Case : TAK
The primary concerns for TAK are Revenue Growth, Return on Equity, Profit Margin. A P/E of 42.5x leaves little room for execution misses. Thin 4.3% margins leave little buffer for downturns.
Key Dynamics to Monitor
AKBA profiles as a turnaround stock while TAK is a value play — different risk/reward profiles.
AKBA carries more volatility with a beta of 0.35 — expect wider price swings.
TAK is growing revenue faster at 3.9% — sustainability is the question.
AKBA generates stronger free cash flow (-21M), providing more financial flexibility.
Bottom Line
TAK scores higher overall (57/100 vs 21/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Akebia Ther
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of kidney therapies for patients with kidney disease. The company is headquartered in Cambridge, Massachusetts.
Takeda Pharmaceutical Co Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?